Archive for 2006/11


New GINA Guidelines Provide Supportive Statements For Symbicort SMART(reg)

The Global Initiative for Asthma (GINA) Scientific Committee has announced the release of an updated version of their international treatment guidelines (Global Strategy for Asthma Management and Prevention) and with them a change in the emphasis as to the recommended treatment approach for asthma.(1) The announced update of the GINA guidelines provides supportive statements for a new management approach to asthma, Symbicort SMARTĀ®, e.g. [click link for full article]
(more...)


American Lung Association Launches Information And Access Program

As a fast-relief inhaler used by millions of Americans with asthma is phased-out for environmental reasons, the American Lung Association today launched an educational and access initiative. The effort will help people with asthma learn about the transition to ozone-friendly, but higher-cost prescription inhalers. [click link for full article]
(more...)


MediciNova Announces The Initiation Of The Phase III Clinical Program For MN-001, A Novel Oral Treatment For Bronchial Asthma

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the initiation of its Phase III clinical program to determine the safety and efficacy of its novel oral treatment for bronchial asthma (MN-001) in asthma patients. The first Phase III trial in this program will involve approximately 705 asthma patients enrolled at 75 - 90 clinical sites in the U.S. [click link for full article]
(more...)


RAND Study Finds Asthma And Lung Disease Patients Receive Half Of Recommended Medical Care

Patients around the United States with obstructive lung diseases receive only about half of the recommended medical care, with care varying significantly based on individual conditions, according to a RAND Corporation study issued on13-Nov-2006.Obstructive lung disease affects an estimated 12 to 50 million Americans and includes asthma and chronic obstructive pulmonary disease (COPD), the most common form being emphysema. [click link for full article]
(more...)


Perceived Control Improves Asthma Health Status

Patients with asthma who believe they have control of their condition are likely to report improved asthma-related health status and have a decreased risk of severe asthma attacks. In a new study out of the University of California, San Francisco, researchers followed 865 patients (mean age 60 years) hospitalized for asthma for a median of 1.9 years after hospital discharge. [click link for full article]
(more...)


Vitamin A No Hlep For Patients With Emphysema

Retinoids, a derivative of vitamin A, may provide little clinical benefit for patients with emphysema, shows a new study. In the "Feasibility of Retinoids for the Treatment of Emphysema" (FORTE) study, researchers from David Geffen School of Medicine in Los Angeles enrolled 148 subjects with moderate-to-severe chronic obstructive pulmonary disease (COPD) with a primary component of emphysema. [click link for full article]
(more...)


GlaxoSmithKline Welcomes New GINA Guidelines For Asthma Management And Prevention

GlaxoSmithKline (GSK) today welcomes new guidelines for Asthma Management and Prevention released today from The Global Initiative for Asthma (GINA). The guidelines emphasise that the overall aim of asthma treatment is to achieve and maintain long-term control of the disease and introduce a new classification of asthma based on levels of control1. Recommended treatment action is then based on the patient's level of control. [click link for full article]
(more...)


Research Finds Antioxidant Therapies Do Not Interfere With Radiation Treatment

Cancer patients can get the vital nutritional benefits from taking antioxidants without the risk of interfering with radiation treatment, according to research findings presented last weekend at the Society of Integrative Oncology's Third International Conference in Boston. The Society for Integrative Oncology is a non-profit organization of oncologists and other health professionals studying and integrating effective complementary therapies in cancer care. [click link for full article]
(more...)


Once- or Twice-Daily Treatment With PULMICORT RESPULES(R) Significantly Increased Percentage of Days Asthma Is Controlled

Children treated with PULMICORT RESPULES(R) (budesonide inhalation suspension) either once or twice daily experienced a significantly greater increase in the percentage of asthma-control days compared to those receiving placebo. These results are being presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia on November 9-15. [click link for full article]
(more...)


Approved Asthma Therapy SYMBICORT Improves Lung Function Safely And Effectively

Newly presented data indicate that treatment with SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) inhalation aerosol results in significantly greater improvements in lung function, and a lower risk of asthma worsening episodes, compared to budesonide and/or formoterol used alone. In addition, data also showed that SYMBICORT was generally well-tolerated, with an adverse event profile similar to that of its individual components. [click link for full article]
(more...)